ALZpath and Alamar Biosciences have expanded their partnership, granting Alamar commercial rights to use ALZpath’s pTau217 antibody in clinical blood tests for Alzheimer’s disease.
The test utilizes genomic sequencing and AI to identify biological signals associated with early-stage disease.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The screening tool identifies specific molecules produced by gut bacteria to distinguish children with autism from typically developing peers.
Read More
The study identifies HAVCR1 as a tool for earlier detection and treatment monitoring for primary central nervous system lymphoma.
Read More
The new kit uses Tasso+ collection technology and certified laboratory analysis to monitor 17 health markers, including blood sugar and lipid levels.
Read More
The sensor identifies misfolded protein biomarkers in blood before clinical symptoms of neurodegeneration appear.
Read More
New research suggests that remote capillary sampling for Alzheimer’s biomarkers correlates with cognitive test performance in older adults.
Read More
Researchers at Mass General Brigham have developed a digital seed amplification assay that detects TDP-43 protein seeds in cerebrospinal fluid, enabling identification of FTLD-TDP, a specific frontotemporal lobar degeneration subtype.
Read More
As diabetes testing evolves, labs are seeing growing interest in earlier screening, additional biomarkers, and tools that can support more preventive care.
Read More
LiquidCell Dx has published research in Nature on LiquidTME, a blood-based assay that profiles the tumor microenvironment and predicts immunotherapy response, potentially offering a noninvasive alternative to tissue biopsy.
Read More
Fujirebio Europe has received CE marking for its automated Lumipulse G pTau 217 Plasma assay, designed to help identify amyloid pathology in patients with cognitive decline, according to the company.
Read More
Mayo Clinic researchers have developed a blood test that detected 93% of germ cell tumors—including cases missed by standard markers.
Read More
VolitionRx reports its lateral flow prototype can detect nucleosomes in finger-prick blood samples from sepsis patients, enabling rapid, point-of-care testing outside centralized labs, according to company data.
Read More
Circular Genomics and Vitazi.ai have formed a partnership to combine AI-driven retinal imaging and blood-based RNA biomarkers for early Alzheimer’s disease detection, aiming to address gaps in early-stage patient identification.
Read More
CareDx will acquire Naveris for $160 million, adding a Medicare-reimbursed liquid biopsy platform for viral-mediated cancer monitoring to its precision medicine portfolio.
Read More
LifeTracDx blood test will evaluate PD-L1 expression changes as exploratory biomarker in trial combining leronlimab with standard therapies.
Read More
Personalis presented data at AACR showing its NeXT Personal assay enabled ultrasensitive ctDNA monitoring for colorectal and lung cancer patients, demonstrating 100% sensitivity at baseline and 100% specificity for relapse post-surgery.
Read More